ASC4KIDS: A Multicenter, Open-Label, Phase 1b/2 Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

被引：0

作者：

Hijiya, Nobuko ^{[1
]}

Heneghan, Mallorie ^{[2
]}

Kapoor, Shruti ^{[3
]}

Dhamal, Vishal ^{[4
]}

Hoch, Matthias ^{[5
]}

Descamps, Laurence ^{[6
]}

Cardoso, Ana Paula ^{[3
]}

Pollard, Jessica ^{[7
]}

机构：

[1] Columbia Univ, Irving Med Ctr, New York, NY USA

[2] Univ Utah, Salt Lake City, UT USA

[3] Novartis Pharmaceut, E Hanover, NJ USA

[4] Novartis Healthcare Private Ltd, Hyderabad, India

[5] Novartis Inst BioMed Res, Basel, Switzerland

[6] Novartis Pharma SAS, Rueil Malmaison, France

[7] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA

来源：

关键词：

CML; asciminib; pediatric patients; TKI; PK; Phase II; trials in progress;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-532

引用

页码：S346 / S347

页数：2